FDA, after turbulent year, leaves drugmakers guessing on its direction
BioPharma Dive
Constant leadership changes and erratic decision-making have left the biopharmaceutical industry feeling its chief regulator is as unpredictable as it s ever been.
pharminent
April 1, 2026 (Last updated: April 1, 2026)
BioPharma Dive
Constant leadership changes and erratic decision-making have left the biopharmaceutical industry feeling its chief regulator is as unpredictable as it s ever been.
